Hostname: page-component-55f67697df-jr75m Total loading time: 0 Render date: 2025-05-12T02:38:47.679Z Has data issue: false hasContentIssue false
  • English
  • Français

Tardive Dyskinesia in Psychiatric Patients Treated with Neuroleptics

Published online by Cambridge University Press:  29 January 2018

Carlo Perris ,
Predrag Dimitrijevic ,
Lars Jacobsson ,
Paul Paulsson ,
Walter Rapp  and
Hans Fröberg
Carlo Perris
Affiliation:
The Departments of Psychiatry, Umea University, Umea, S– 901 85 Sweden
Predrag Dimitrijevic
Affiliation:
The Departments of Psychiatry, Umea University, Umea, S– 901 85 Sweden
Lars Jacobsson
Affiliation:
The Departments of Psychiatry, Umea University, Umea, S– 901 85 Sweden
Paul Paulsson
Affiliation:
The Departments of Psychiatry, Umea University, Umea, S– 901 85 Sweden
Walter Rapp
Affiliation:
The Departments of Psychiatry, Umea University, Umea, S– 901 85 Sweden
Hans Fröberg
Affiliation:
The Departments of Psychiatry, Umea University, Umea, S– 901 85 Sweden
Get access Rights & Permissions [Opens in a new window]

Summary

The point prevalence of tardive dyskinesia (TD) as assessed by means of the Simpson rating scale was determined for 14 psychiatric wards with 347 patients (213 and 134 female) at the time of the study. TD was found to occur in 17.3 per cent of the patients, the prevalence being significantly higher in female than in male patients. The frequency of TD increases with age.

A random group of TD patients was matched with a group of patients without TD and the total medication for both groups was calculated. No differences were found as concerns total amount of high or low dosage neuroleptics, or anticholinergic drugs, for the two groups. However, significantly more TD patients than controls had received dosage neuroleptics, or anticholinergic drugs for the two groups. However significantly more TD patients than controls had received anticholinergic drugs.

There was no significant relationship between severity of TD: age, duration of treatment, total amount of high or low dosage neuroleptics. On the other hand a significant relationship was found between severity of TD and amount of anticholinergic drugs. Significantly more patients in the TD-group than in the control group had a past history which might suggest possible brain damage prior to the neuroleptic medication.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 135 , Issue 6 , December 1979 , pp. 509 - 514
Copyright
Copyright © Royal College of Psychiatrists, 1979 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Aquilonius, S. M. & Sjöström, R. (1971) Cholinergic and dopaminergic mechanisms in Huntington's Chorea. Life Science, 10, 405–14.Google ScholarPubMed
Barbeau, A. (1973) Biochemistry of Huntington's chorea in advances. In Advances in Neurology, Vol. I. pp. 473–516. New York: Raven Press.Google Scholar
Brandon, S., McClelland, H. A. & Protheroe, C. (1971) A study of facial dyskinesia in a mental hospital population. British Journal of Psychiatry, 118, 171–84.CrossRefGoogle Scholar
Crane, G. E. (1968) Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. American Journal of Psychiatry, 124, 40–8.CrossRefGoogle ScholarPubMed
Crane, G. E. (1973) Persistent dyskinesia. British Journal of Psychiatry, 122, 395–405.CrossRefGoogle ScholarPubMed
Crane, G. E. & Paulson, G. (1967) Involuntary movements in a sample of chronic mental patients and their relation to the treatment with neuroleptics. International Journal of Neuropsychiatry, 3, 286–91.Google Scholar
Edwards, H. (1970) The significance of brain damage in persistent oral dyskinesia. British Journal of Psychiatry, 116, 271–5.CrossRefGoogle ScholarPubMed
Eicke, W. J. (1956) Beitrag zu der Mitteilung von Kulenkampff und Tarnow. Nervenarzt, 27, 418–19.Google Scholar
Faurbye, A., Rasch, P. J., Petersen, P. B., Brandborg, G. & Pakkenberg, H. (1964) Neurological symptons in pharmacotherapy of psychoses. Acta Psychiatrica Scandinavica, 40, 10–27.CrossRefGoogle Scholar
Gardos, E., Cole, J. O. & La Brie, R. (1977) The assessment of tardive dyskinesia. Archives of General Psychiatry, 34, 1206–1212.CrossRefGoogle ScholarPubMed
Gerlach, J. (1977) Tardive dyskinesia. Nordisk Psykiatrisk Tidskrift, 31, 394–9.Google Scholar
Gerlach, J., Reisby, N. & Randrup, A. (1974) Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia, 34, 21–55.CrossRefGoogle ScholarPubMed
Haddenbrock, S. (1964) Prolonged hyperkinetic syndromes following longterm treatment with high doses of neuroleptic agents. In Begleitwirkungen und Misserfolge der psychiatrischen Pharmakotherapie (eds. Kranz, H. and Heinrich, K.). pp. 54–63. Stuttgart: G. Thieme.Google Scholar
Heinrich, K., Wegener, I. & Bender, H. J. (1968) Spate extrapyramidale hyperkinesen bei neuroleptischer Langzeit-therapie. Pharmakopsychiatrie Neuro-Psychopharmakologie, 1, 169–95.CrossRefGoogle Scholar
Hippius, H. & Lange, J. (1970) Zur Problematik der späten extrapyramidalen Hyperkinesen nach langfristiger neuroleptischer Therapie. Arzneimittelforschung, 20, 888–90.Google Scholar
Kennedy, P. F., Hershon, H. I. & McGuire, R. J. (1971) Extrapyramidal disorders after prolonged phenothiazine therapy. British Journal of Psychiatry, 118, 509–18.CrossRefGoogle ScholarPubMed
Kiloh, L. G., Smith, J. S. & Williams, S. E. (1973) Anti-parkinson drugs as causal agents in tardive dyskinesia. Medical Journal of Australia, 2, 591–3.CrossRefGoogle ScholarPubMed
Klawans, H. L. (1970) A pharmacologic analysis of Huntington's Chorea. European Neurology, 4, 148–63.CrossRefGoogle ScholarPubMed
Klawans, H. L. (1973) The pharmacology of tardive dyskinesia. American Journal of Psychiatry, 130, 82–6.CrossRefGoogle Scholar
Kulenkampff, C. & Tarnow, G. (1956) ‘Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation’. Nervenarzt, 27, 178–80.Google Scholar
Lehman, H. L., Ban, T. A. & Saxena, B. M. (1970) A survey of extrapyramidal manifestations in the inpatient population of a psychiatric hospital. Lával Medical, 41, 909–16.Google Scholar
Nielsen, E. B. & Lyon, M. (1978) Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug flupenthixol in rats. Psychopharmacology, 59, 85–90.CrossRefGoogle ScholarPubMed
Ogita, K., Yagi, G., Itoh, H., Miura, S. & Lambert, P. A. (1975) Comparative analysis of persistent dyskinesias of long-term usage with neuroleptics in France and in Japan. Folia Psychiatrica Neurologica Japanica, 29, 316–20.Google ScholarPubMed
Sigwald, J., Boultier, D., Raymondeand, C. & Piot, C. (1959) Quatre cas de dyskinésie facio-bucco-linguo-masticatrice à évolution prolongée secondaire à un traitement par les neuroleptiques. Review of Neurology, 100, 751–5.Google Scholar
Simpson, G. M., Lee, J. H., Zoubok, B. & Gardos, G. (1979) A rating scale for tardive dyskinesia. Psycho-pharmacology (in press).CrossRefGoogle Scholar
Tarsy, D. & Baldessarini, R. J. (1976) The Tardive Dyskinesia Syndrome. In Clinical Neuropharmacology 1. pp. 29–61. (ed. Klavaus, H. L.). New York: Raven Press.Google Scholar
Tarsy, D., Granacher, R. & Brawloer, M. (1977) Tardive dyskinesia in young adults. American Journal of Psychiatry, 134, 1032–4.Google ScholarPubMed
Turunen, S. & Achté, K. A. (1967) The bucco-linguo-masticatory syndrome as side effect of neuroleptic therapy. Psychiatry Quarterly, 41, 268–80.CrossRefGoogle Scholar
Uhrbrand, L. & Faurbye, A. (1960) Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine, and ECT. Psychopharmacologia, i, 408–18.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.